v3.26.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 26, 2026
Jul. 27, 2025
Jul. 26, 2026
Jul. 27, 2025
Jan. 25, 2026
Jan. 26, 2025
Cash flows from operating activities:            
Net income $ 160,121 $ (27,064) $ 186,684 $ (7,719)    
Adjustments to reconcile net income (loss) to net cash provided by operating activities:            
Depreciation and amortization     18,915 20,504    
Amortization of right-of-use assets     3,168 2,702    
Goodwill impairment 0 41,991 0 41,991    
Accretion of deferred financing costs     2,144 2,525    
Write-off of deferred financing costs 193 364 193 516    
Interest rate swap termination     0 (729)    
Deferred income taxes     (107,002) 4,848    
Share-based compensation     50,292 24,132    
Loss on disposition of business operations and assets     5 42    
Equity method income (4,096) 62 (5,717) (984)    
Gain from sale of investments     (100) 0    
Corporate-owned life insurance, net     4,068 1,389    
Changes in assets and liabilities:            
Accounts receivable, net     (35,021) 9,218    
Inventories     (5,997) (19,628)    
Other assets     (17,447) (2,770)    
Accounts payable     13,245 11,225    
Accrued liabilities     1,232 (11,440)    
Other liabilities     (3,591) (3,603)    
Net cash provided by operating activities     105,071 72,219    
Cash flows from investing activities:            
Proceeds from sales of property, plant and equipment     46 3    
Purchase of property, plant and equipment     (15,663) (4,534)    
Proceeds from sale of investments     100 536    
Purchase of intangibles     (5,986) (2,779)    
Acquisitions, net of cash acquired     (36,306) 0    
Premiums paid for corporate-owned life insurance     0 (3,428)    
Net cash used in investing activities     (57,809) (10,202)    
Cash flows from financing activities:            
Proceeds from revolving line of credit     50,000 0   $ 68,300
Payments of revolving line of credit     (50,000) 0    
Payments of term loans     0 (35,000)    
Proceeds from interest rate swap termination     0 237    
Deferred financing costs     (2,287) (564)    
Payments for employee share-based compensation payroll taxes     (37,213) (12,191)    
Proceeds from exercise of stock options     1,133 500    
Net cash used in financing activities     (38,367) (47,018)    
Effect of foreign exchange rate changes on cash and cash equivalents     (23) 1,818    
Net increase in cash and cash equivalents     8,872 16,817    
Cash and cash equivalents at beginning of period     195,179 151,743 $ 151,743  
Cash and cash equivalents at end of period $ 204,051 $ 168,560 204,051 168,560 $ 195,179 $ 151,743
Supplemental disclosure of cash flow information:            
Interest paid     1,535 10,035    
Income taxes paid     6,735 3,996    
Non-cash investing and financing activities:            
Accounts payable related to capital expenditures     468 507    
Accrued deferred financing costs     455 0    
Accrued purchases of intangibles     111 3,652    
Acquisition related holdback liability     $ 4,000 $ 0